Please login to the form below

Not currently logged in
Email:
Password:

Intercept Pharmaceuticals

This page shows the latest Intercept Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

Intercept Pharmaceuticals is awaiting a US Food and Drug Administration (FDA) review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again

Latest news

  • Genfit scraps phase 3 trial of experimental NASH drug Genfit scraps phase 3 trial of experimental NASH drug

    Another potential competitor – Intercept Pharmaceuticals – is still awaiting an FDA review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again in

  • FDA delays decision on Intercept's NASH drug by three months FDA delays decision on Intercept's NASH drug by three months

    Action date pushed back to 26 June. The US Food and Drug Administration (FDA) has pushed back the date on which it is due to decide whether to approve Intercept Pharmaceuticals’ ... additional information provided in response to FDA requests,”

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    Ocaliva approved as a combination treatment for primary biliary cholangitis. Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both sides of the ... Intercept launched Ocaliva in the US

  • Gilead chalks up trial success for new NASH drug Gilead chalks up trial success for new NASH drug

    The company is vying with rivals such as Allergan and Intercept Pharmaceuticals in its pursuit of the NASH market. . ... Allergan has been building a pipeline of candidates through a series of bolt-on acquisitions including Akarna Therapeutics and

  • Takeda enlists GE's aid to tackle liver fibrosis epidemic Takeda enlists GE's aid to tackle liver fibrosis epidemic

    Takeda is playing catch-up in the liver fibrosis race, with rivals such as Gilead Sciences, Intercept Pharmaceuticals, Galectin Therapeutics and Genfit already having compounds in the clinic. ... Gilead's simtuzumab is in phase II testing in NASH, while

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Simon Doyle joins STEM Simon Doyle joins STEM

    Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help

  • Glenn Sblendorio to retire as president of The Medicines Company Glenn Sblendorio to retire as president of The Medicines Company

    He has over 20 years of experience in the pharmaceutical industry and prior to joining The Medicines Company held senior managing and financial positions at Eyetech Pharmaceuticals and MPM Capital Advisors. ... He currently serves as a director at Amicus

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....